A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
Sponsor: AbbVie
Listed as NCT02955212, this PHASE3 trial focuses on Rheumatoid Arthritis (RA) and remains completed. Sponsored by AbbVie, it has been updated 24 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
24 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
▶ Show 19 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Feb 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Apr 2019 [monthly]
Recruiting PHASE3
-
Oct 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE3
-
May 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baotou, China , Beijing, China , Bengbu, China , Changchun, China , Changsha, China , Changzhou, China , Chengdu, China , Cheonan-si, South Korea , Curitiba, Brazil , Daegu, South Korea and 26 more locations